B. Riley says Eli Lilly’s (LLY) deal to acquire Point Biopharma (PNT) validates the value of late-stage radiopharmaceuticals assets. The acquisitions shows Lilly’s strategic interest in targeted radiotherapeutics, especially alpha emitters, which reads positively to radiopharma names Actinium Pharmaceuticals (ATNM), Fusion Pharmaceuticals (FUSN), and Lantheus (LNTH), the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ATNM:
- Actinium presents updated survival data from Phase 2b trial of Actimab-A
- Actinium Pharmaceuticals initiated with a Buy at HSBC
- Actinium price target lowered to $50 from $53 at H.C. Wainwright
- Actinium Pharmaceuticals files $500M mixed securities shelf
Questions or Comments about the article? Write to editor@tipranks.com